Aptus Pharma Limited
Bookbuilding IPO · BSE
- Price band
- ₹65 - ₹70
- Lot size
- 2,000 shares
- Issue amount
- ₹13.02 cr
- Total subscription
- 3.75×
- Opens
- 23 Sept 2025
- Closes
- 25 Sept 2025
- Allotment
- 26 Sept 2025
- Listing
- 30 Sept 2025
Offer at a glance
Issue overview
- Issue size
- 18,60,000 shares
- Face value
- ₹10 per share
- Minimum investment
- ₹1,30,000
- Fresh issue
- ₹13.02 cr
- Offer for sale
- ₹0 cr
- Registrar
- Bigshare Services Private Limited
- Listing exchange
- BSE
- Maximum investment
- ₹1,40,000
- Issue type
- Bookbuilding IPO
- Shares before issue
- 50,00,000
- Shares after issue
- 68,60,000
Lot sizes
| Category | Lots | Shares | Amount |
|---|---|---|---|
| RETAIL | 2 | 4,000 | ₹2,80,000 |
| sHNI | 3 | 6,000 | ₹4,20,000 |
| bHNI | 8 | 16,000 | ₹11,20,000 |
Share reservation
Subscription & GMP
Subscription by category
Reported 24 Sept 2025
GMP history
Day-wise demand
Application-wise demand
| Category | Reserved applications | Applied applications |
|---|---|---|
| QIB | 0 | 2 |
| NIB | 0 | 629 |
| RETAIL | 155 | 4,608 |
| HNIs(10L +) | 30 | 323 |
| HNIs (2-10L) | 15 | 306 |
Subscription demand
Amounts in ₹ crore. HNI subcategories are included in the NII total.
| Category | Offered | Demand |
|---|---|---|
| QIBs | 2.46 | 3.01 |
| FIIs | 0 | 3.01 |
| RETAIL | 4.34 | 129.75 |
| HNIs 2+ | 0.62 | 14.56 |
| HNIs 10+ | 1.25 | 38.84 |
Financial performance
Company financials
In Crores · Reported periods may include interim results.
Key performance indicators
| Metric | Mar-25 | Mar-24 | Mar-23 |
|---|---|---|---|
| EPS | 6.37 | 5.32 | 1.3 |
| ROE | 44.5 | 45.18 | 20.06 |
| ROCE | 45.66 | 21.7 | 12.77 |
| RONW | 0 | 0 | 0 |
| PRE IPO(PE) | 11.29 | 0 | 0 |
| POST IPO(PE) | 15.49 | 0 | 0 |
Values and labels as reported in the issue data.
Peer comparison
| Company | P/E(X) | CMP* (₹) | Face value (₹) | NAV/Share (₹) | RONW(%) | EPS (Basic) (₹) |
|---|---|---|---|---|---|---|
| Zota health care limited | 382.12 | 1,207.50 | 10 | 110.83 | 2.72 | 3.16 |
| Aptus Pharma Limited | NA | NA | 10 | 13.93 | 44.5 | 5.32 |
| Sunrest Lifescience Limited | 10.56 | 49.2 | 10 | 37.72 | 12.36 | 4.66 |
| Lincoln Pharmaceuticals Limited | 13.53 | 556.1 | 10 | 335.34 | 12.26 | 41.11 |
Company information
Company profile
Aptus Pharma Ltd, incorporated in 2010, is engaged in the marketing and distribution of finished pharmaceutical formulations. The company manufactures and distributes a wide range of products across multiple therapeutic areas including antacids and PPIs, pain management, anti-inflammatories, antibiotics, cardiology and antidiabetics, neuropsychiatry, dental, injectable parenterals, syrups, nutraceuticals, and sachets. Its business divisions include Aptus Pharma, which focuses on acute therapies such as anti-infectives and pain management; Aptus CD Care, which specializes in chronic therapies; Aptus Wellcare, which offers wellness and nutraceutical products; and Aptus Global, which caters to the export market. As of March 31, 2025, the company had developed 194 pharmaceutical formulations across more than eleven therapeutic segments. It operates warehouses covering 15,732 sq. feet and 1,989 sq. feet in Ahmedabad, Gujarat. The company’s distribution network consists of 125 direct and sub-distributors supported by a sales team of 54 field personnel, and it employed 70 people as of March 31, 2025.
Strengths
- Diverse Product Range – Offers 194+ pharmaceutical formulations across 11+ therapeutic segments, catering to varied patient and healthcare requirements.
- Robust Distribution Network – Central warehouse in Ahmedabad and logistics partnerships enable safe, timely, and efficient delivery across target markets.
- High-Quality Compliance – Adheres to WHO-GMP protocols with rigorous testing at all production stages, ensuring consistent, safe, and credible products.
Risk factors
- Regulatory Compliance Risk – Inability to obtain, renew, or maintain required statutory and regulatory approvals could disrupt operations and affect financial performance.
- Customer Dependence Risk – Heavy reliance on a few key customers exposes revenue to potential declines if contracts are reduced or terminated.
- Intellectual Property Risk – Failure to protect intellectual property or facing infringement claims may lead to sales loss, liabilities, and negative financial impact.
Promoters
Tejash Maheshchandra Hathi
Chatrabhuj Vallabhbhai Butani
Kapilbhai Hasmukhbhai Chandarana
Ghanshyam Vinubhai Pansuriya
Milly Chetan Lalseta
Riddhish Natwarlal Tanna
Gaurang Rameshchandra Thakker
Kripaliben Mayank Thakker
Kunjal Piyushbhai Unadkat
Registrar & documents
Lead manager
Interactive Financial Services Limited
Registrar & contacts
Bigshare Services Private Limited
[email protected]Official registrar portal ↗IPO allotment status guide →Registered office
Ashutosh Buildcon, Opp. Slok - 2, Nr. Harikrupa Logistic Park, Aslali, Ahmedabad, Daskroi, Ahmedabad, Gujarat, 382427
+91 76004 27827
[email protected]Company website ↗Understanding APPL IPO data
Compare the price band and required investment with the company profile, financial results and offer documents. Subscription figures show reported demand by category; they do not establish the value of the business. GMP is an unofficial indication and can change before listing.